Wednesday, July 8, 2026

Patent intelligence · US

US 8227230

Human lysosomal proteins from plant cell culture

granted A61KA61K36/23A61K38/47A61K9/0053
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 6
Applicant portfolio 22
Patent details — US 8227230
Jurisdiction
US
Status
granted
Grant date
Jul 24, 2012
Expiration
Jul 19, 2032
Applicant
Protalix Ltd.
Claims
8
CPC classes
A61K, A61K36/23, A61K38/47, A61K9/0053
View on Google Patents ↗

Quick answer

US 8227230 (Human lysosomal proteins from plant cell culture) is held by Protalix Ltd.. Status: granted. Granted Jul 24, 2012. Expires Jul 19, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Protalix Ltd.
Grant date
Expiration
Claims
8
CPC classes
A61K, A61K36/23, A61K38/47, A61K9/0053, A61P, A61P1/16

More from Protalix Ltd.

Related pharmaceutical patents in our USPTO index.

  1. US 12385026

    Stabilized alpha-galactosidase and uses thereof

    Protalix Ltd. · Expires Aug 7, 2045

    granted
  2. US 12194079

    Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase

    Protalix Ltd. · Expires Jan 9, 2045

    granted
  3. US 11814657

    Modified DNase and uses thereof

    Protalix Ltd. · Expires Nov 9, 2043

    granted
  4. US 11225648

    Modified DNase and uses thereof

    Protalix Ltd. · Expires Jan 13, 2042

    granted
  5. US 10870842

    Stabilized alpha-galactosidase and uses thereof

    Protalix Ltd. · Expires Dec 17, 2040

    granted
  6. US 10730925

    Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same

    Protalix Ltd. · Expires Jul 30, 2040

    granted
  7. US 10280414

    Stabilized α-galactosidase and uses thereof

    Protalix Ltd. · Expires May 2, 2039

    granted
  8. US 10087232

    Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy

    Protalix Ltd. · Expires Sep 27, 2038

    granted

Frequently asked questions

What is US patent 8227230?

US 8227230 (Human lysosomal proteins from plant cell culture) is held by Protalix Ltd.. Status: granted. Granted Jul 24, 2012. Expires Jul 19, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8227230?

Protalix Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 22 pharmaceutical patents for this assignee.

When does US 8227230 expire?

Our index shows an expiration date of Jul 19, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.